On October 05, 2021, Boehringer Ingelheim’s new state-of-the-art production facility was officially opened during a virtual event.
The new production building, called LSCC (Large Scale Cell Culture), will produce biopharmaceutical active ingredients for the manufacture of drugs against heart attacks, strokes and cancer for the global market.
Read more about it in the Standard:
The project in figures:
- 700 million euros investment volume
- 500 new jobs at the Vienna site
- 4 years construction time
Our services in the course of the project: Accompanying control and cost management
